Sign Up
Stories
Aspira Women’s Health Secures Distribution Agreement
Share
Asia Pacific Poised for Diagnostics Grow...
Biotechnology and Skin Cancer Detection ...
Carrier Screening Market Set to Reach US...
Asia-Pacific EV-Based Liquid Biopsy
Autoimmune Disease Diagnostics Market Gr...
CVS Health to Offer Free Birth Control
Overview
API
Aspira Women’s Health secures a 5-year distribution agreement with Hi-Precision Laboratories in the Philippines, granting them exclusive rights to market and distribute the OvaSuiteSM portfolio. The agreement involves royalties for each test performed, aligning with Aspira's focus on developing noninvasive, AI-powered tests for gynecologic diseases.
Ask a question
How might this distribution agreement impact the availability and accessibility of noninvasive AI-powered tests for gynecologic diseases in the Philippines?
In what ways could the distribution agreement with Hi-Precision Laboratories influence the healthcare landscape in the Philippines and beyond?
What are the potential implications of Aspira Women’s Health's focus on developing noninvasive AI-powered tests for gynecologic diseases on the healthcare industry's approach to diagnosing and treating these conditions?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage